Understanding the Serum Free Light Chain Assays. Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc.

Size: px
Start display at page:

Download "Understanding the Serum Free Light Chain Assays. Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc."

Transcription

1 Understanding the Serum Free Light Chain Assays Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc.

2 AL Amyloidosis: abnormality of proteins from Plasma Cells in the Bone Marrow Red Blood Cells Soft blood-forming tissue that fills the cavities of bone White Blood Cells: (B lymphocytes/ Plasma cells) Platelets

3 Plasma Cells produce Antibodies and Free Light Chains Kappa Lambda

4 Antibodies Are Made Up Of Heavy Chains And Light Chains Immunoglobulin (Antibody) Light Chains Heavy Chains

5 There Are Two Types Of Light Chains Kappa And Lambda Kappa Free Light Chains Lambda Free Light Chains

6 Cancer. 1956;9: Korngold Kappa Lipari Lambda

7 Normal vs AL Amyloidosis Normal Lots of different types of whole antibodies AL Amyloidosis Too much of a Toxic, precipitating light chain produced

8 What is AL Amyloidosis? AL = Antibody Light chain (a disease of protein misfolding) Amyl oid = Starch-like (Greek)

9 Primary [AL] Amyloidosis is a plasma cell disorder Kappa Lambda Kappa Abnormal Lambda Lambda Normal Healthy Plasma cells Mutated (diseased) Plasma cells

10 These abnormal light chains have mutations which make them sticky Multiple Myeloma FDG PET: Severe Diffuse (D) and Focal (F) Disease A F They bind together to form an amyloid protein complex B Amyloid proteins D accumulate D in target organs such as the D D HEART and KIDNEYS D D

11 AL Amyloidosis In AL amyloidosis, proteins which deposit can damage critical organs (e.g., heart, kidneys) Important to use testing to monitor disease and guide therapy

12 Free Light Chain Review Free light chains are normally found in the blood. Free light chains circulate in the blood at abnormally high levels in many patients with AL amyloidosis. Levels of FLCs are associated with the number of malignant plasma cells in a patient with AL Amyloid. In AL Amyloid, abnormal free light chains stick together to form amyloid protein which can damage important organs like the kidneys and heart.

13 Types of Systemic Amyloidosis Primary (AL) Amyloidosis Kappa or Lambda Immunoglobulin light chain associated Secondary (AA) Amyloidosis Amyloidosis secondary to another disorder (such as RA, psoriatic arthritis, inflammatory bowel disease, TB, leprosy, osteomyelitis, bronchiectasis) Serum Amyloid A associated Hereditary Amyloidosis Associated with certain genotypes TTR mutant transthyretin associated More than 25 different amyloid proteins have been identified!

14 Relative Frequency All All Others Others 15% 15% AL AL Amyloidosis 85% Amyloidosis 85%

15 Amyloidosis Incidence AL Amyloidosis Incidence in the population 1/5 th of Multiple Myeloma (Annual Incidence AL 9 per million per year) Palumbo, A, Rajkumar SV. Leukemia 23: Kyle, RA, Rajkumar SV. N. Engl. J of Med 351: Bradwell, Serum Free Light Chain Analysis, 5 th ed, 2008, p 125

16 Overlapping Diseases AL Amyloidosis BOTH! Myeloma

17 Amyloid The definitive diagnostic test for amyloidosis is a tissue biopsy showing apple green birefringence when stained with congo red dye and viewed under a microscope using polarized light Pink deposits when stained with hematoxylin and eosin The pink deposits appear apple green with congo red staining and polarized light Glomerular amyloidosis

18 Plasma Cells Produce Intact Antibodies AND Free Light Chains Intact Antibodies Tests SPE and IFE Free light chain test = Freelite Plasma Cell Free Light Chains

19 The FreeLite Test Measures both types of Free Light Chains Kappa Free Light Chains Lambda Free Light Chains

20 FREELITE : Polyclonal Sheep Abs Only Bind to Free Light Chains Kappa Hidden surface heavy chain Antibody target Antibody target light chain Lambda

21 Total Light Chain Assay

22 Normal Ranges for Serum Free Light Chains Units (mg/l) Kappa: mg/l Units (mg/dl) Kappa: mg/dl Lambda: mg/l Lambda: mg/dl / ratio: / ratio:

23 Examples May July = 385 mg/l

24 THERAPY AL amyloidosis Therapy KILLS ABNORMAL PLASMA CELLS LESS ABNORMAL PLASMA CELLS = FEWER LIGHT CHAINS + LESS AMYLOID

25 Lab Reports

26 Laboratory Variability Absolute values in the serum free light chain assay can vary from lab to lab Different analytical instruments Different kits for different instruments Normal lab to lab variation

27 Laboratory Variability If you change the laboratory where your serum free light chains are measured: If possible, obtain some of the last sample and run it along with the new sample or Establish a new baseline for your serum free light chain levels. The change in your absolute sflc level should not effect the clinical interpretation.

28 Additional Resources (web version of our red book ) Google Binding Site us info@thebindingsite.com Call The Binding site Experts are on hand to assist you Understanding Serum Free Light Chain Assays (IMF booklet)

29 Q & A

Freelite SFLC in CKD why use a different reference range? Dr Colin Hutchison Nephrologist Hawke s Bay DHB

Freelite SFLC in CKD why use a different reference range? Dr Colin Hutchison Nephrologist Hawke s Bay DHB Freelite SFLC in CKD why use a different reference range? Dr Colin Hutchison Nephrologist Hawke s Bay DHB Disclosures I have only really worked with the Freelite assays Previous research funding, technical

More information

Serum free light chain (SFLC) assays. Dr Sarah Sasson SydPath Registrar

Serum free light chain (SFLC) assays. Dr Sarah Sasson SydPath Registrar Serum free light chain (SFLC) assays Dr Sarah Sasson SydPath Registrar Introduction to SFLC Plasma cell dyscrasias such as monoclonal gammopathy of uncertain significance (MGUS) smouldering/asymptomatic

More information

Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial

Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial Jill Corre*, Thomas Dejoie, Helene Caillon, Michel Attal*,

More information

EDEMA IN A PATIENT WITH RECURRENT RESPIRATORY INFECTIONS - Case Report

EDEMA IN A PATIENT WITH RECURRENT RESPIRATORY INFECTIONS - Case Report EDEMA IN A PATIENT WITH RECURRENT RESPIRATORY INFECTIONS - Case Report Alain SOUPART, MD, PhD, FACP.hon Department of General Internal Medicine, Jolimont/Tubize and Erasmus University Hospital, Free University

More information

Serum Free Light Chain Assay

Serum Free Light Chain Assay Serum Free Light Chain Assay This Infosheet explains what light chains are, what the Serum Free Light Chain Assay is, and why it is used in AL amyloidosis. In AL amyloidosis, abnormal plasma cells in the

More information

Diagnosis of Amyloidosis. Maria M. Picken MD, PhD Loyola University Medical Center Chicago

Diagnosis of Amyloidosis. Maria M. Picken MD, PhD Loyola University Medical Center Chicago Diagnosis of Amyloidosis Maria M. Picken MD, PhD Loyola University Medical Center Chicago mpicken@lumc.edu 1 Outline Diagnosis of amyloidosis Fat pad Other 2 Amyloidoses protein folding disorders protein

More information

Laboratory Examination

Laboratory Examination Todd Zimmerman, M.D. 64 year old African American male presents to establish care with PCG. Meds: Norvasc 5 mg daily PMHx: HTN x 20 years, poorly controlled SHx: No tobacco, illicit; rare EtOH ROS: Negative

More information

Amyloidosis: What to do and how to diagnose: An Update 2017

Amyloidosis: What to do and how to diagnose: An Update 2017 Amyloidosis: What to do and how to diagnose: An Update 2017 Jonathan L. Kaufman, MD Associate Professor Hematology & Oncology Winship Cancer Institute of Emory University Amyloidosis Protein Conformation/Deposition

More information

Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM

Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM Multiple myeloma Response evaluation Kumar Lancet Oncol 2016; 17: e328 46 Cumulative Proportion Surviving

More information

Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple

Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple Joan Bladé Unidad de Amiloidosis y Mieloma Servicio de Hematología Hospital Clínic de Barcelona Málaga, 16 de noviembre

More information

Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT

Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT The Kidney in Multiple Myeloma Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT Normal Cell Plasma cells produce antibodies that bind to antigens,

More information

Multiple Myeloma 101: Understanding Your Labs

Multiple Myeloma 101: Understanding Your Labs Multiple Myeloma 101: Understanding Your Labs Tim Wassenaar MD MS Hematologist, Director of Clinical Trials UW Cancer Center at ProHealth Care None Disclosures Outline Define hematopoiesis WBCs, RBCs,

More information

Glistening, Skin-Colored Nodule

Glistening, Skin-Colored Nodule To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/436334 Medscape Dermatology Clinic Glistening, Skin-Colored Nodule

More information

Sheena Surindran Grand Rounds 2/15/11

Sheena Surindran Grand Rounds 2/15/11 Sheena Surindran Grand Rounds 2/15/11 Affects 5 12 person per million / year 5 10% associated with myeloma Median survival without treatment is 12 40 months Most commonly affected organs are kidney, heart

More information

Amyloidosis. Maria M. Picken MD, PhD

Amyloidosis. Maria M. Picken MD, PhD Amyloidosis Goals: To explain how amyloid forms and what diseases are caused by it Objectives 1. Explain why amyloid forms 2. When to suspect amyloidosis 3. How to diagnose amyloidosis 4. What are the

More information

Amyloidosis Information. A General Overview for Patients

Amyloidosis Information. A General Overview for Patients Amyloidosis Information A General Overview for Patients www.amyloidosis.org Amyloidosis was first discovered 150 years ago by the well know German pathologist, Dr. Rudolf Virchow. Although the disease

More information

Multiple Myeloma Advances for clinical pathologists & histopathologists

Multiple Myeloma Advances for clinical pathologists & histopathologists Multiple Myeloma Advances for clinical pathologists & histopathologists CME in Haematology 2014 IAPP & Dept of Pathology, BVDUMC, Pune Sunday, 4 th May 2014 Dr. M.B. Agarwal, MD, MNAMS Head, Dept of Haematology

More information

Clinical history. 73 yo man with chest pain Systemic hypertension and WG Stress EKG N Stress echocardiogram: Cardiac catheterization: no CAD

Clinical history. 73 yo man with chest pain Systemic hypertension and WG Stress EKG N Stress echocardiogram: Cardiac catheterization: no CAD CASE 8 Clinical history 73 yo man with chest pain Systemic hypertension and WG Stress EKG N Stress echocardiogram: Concentric hypertrophy Hypokinesis of LV-Inf Cardiac catheterization: no CAD Technique

More information

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016 + M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016 + Disclosures Advisory Boards: AMGEN, Lundbeck, NOVARTIS + Subtypes of Plasma Cell Disorders Increased Plasma

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016 MYELOMA Quantitative Markers-Myeloma Assessment Quantitative markers are biochemicals that are recorded in tests on body fluids such as serum and urine. Applicable Disease Sites The myeloma disease site

More information

Case Report Diaphragmatic Amyloidosis Causing Respiratory Failure: A Case Report and Review of Literature

Case Report Diaphragmatic Amyloidosis Causing Respiratory Failure: A Case Report and Review of Literature Volume 2015, Article ID 917157, 4 pages http://dx.doi.org/10.1155/2015/917157 Case Report Diaphragmatic Amyloidosis Causing Respiratory Failure: A Case Report and Review of Literature Aleksey Novikov,

More information

Hematology 101. Rachid Baz, M.D. 5/16/2014

Hematology 101. Rachid Baz, M.D. 5/16/2014 Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More

More information

Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias

Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic eva.honsova@ikem.cz Plasma cell dyscrasias Plasma

More information

Interesting case seminar: Native kidneys Case Report:

Interesting case seminar: Native kidneys Case Report: Interesting case seminar: Native kidneys Case Report: Proximal tubulopathy and light chain deposition disease presented as severe pulmonary hypertension with right-sided cardiac dysfunction and nephrotic

More information

Serum Levels of Free Light Chain before and after Chemotherapy in Primary Systemic AL Amyloidosis

Serum Levels of Free Light Chain before and after Chemotherapy in Primary Systemic AL Amyloidosis ORIGINAL ARTICLE Serum Levels of Free Light Chain before and after Chemotherapy in Primary Systemic AL Amyloidosis Masayuki MATSUDA, Toshiyuki YAMADA**, Takahisa GONO, Yasuhiro SHIMOJIMA, Wataru ISHII,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_ transplantation_for_primary_amyloidosis 2/2001 11/2018 11/2019 11/2018 Description

More information

FIBRILLARY GLOMERULONEPHRITIS DIAGNOSTIC CRITERIA, PITFALLS, AND DIFFERENTIAL DIAGNOSIS

FIBRILLARY GLOMERULONEPHRITIS DIAGNOSTIC CRITERIA, PITFALLS, AND DIFFERENTIAL DIAGNOSIS FIBRILLARY GLOMERULONEPHRITIS DIAGNOSTIC CRITERIA, PITFALLS, AND DIFFERENTIAL DIAGNOSIS Guillermo A. Herrera MD Louisiana State University, Shreveport Fibrils in bundles 10-20 nm d Diabetic fibrillosis

More information

MYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose

MYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose I have no conflicts of interest to disclose MYE FORMS REVEALED Janet Brunner, PA-C CIBMTR MKE New10_1.ppt OBJECTIVES 1) Be able to describe the criteria required for each myeloma response code 2) Be able

More information

Familial Mediterranean Fever. By:Ismaeel Qattam

Familial Mediterranean Fever. By:Ismaeel Qattam Familial Mediterranean Fever By:Ismaeel Qattam FMF : It s characterized by auto inflammatory condition that causes recurrent fevers and painful inflammation of the abdomen, lungs, joints, etc. It s an

More information

Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis

Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis ORIGINAL PAPERS Adv Clin Exp Med 2014, 23, 4, 531 538 ISSN 1899 5276 Copyright by Wroclaw Medical University Lidia Usnarska-Zubkiewicz 1, A, C F, Jadwiga Hołojda 2, B C, F, Jakub Dębski 3, B, Anna Zubkiewicz-Zarębska

More information

CASE REPORT Light chain multiple myeloma: an evaluation of its biochemical investigations

CASE REPORT Light chain multiple myeloma: an evaluation of its biochemical investigations Malaysian J Pathol 2017; 39(3) : 311 315 CASE REPORT Light chain multiple myeloma: an evaluation of its biochemical investigations Siti Yazmin ZAHARI SHAM BM, MPath, Subashini C. THAMBIAH MBBS, MPath,

More information

A.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)

A.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified) chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst

More information

Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD

Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD Department of Oncology & Hematology AZ Nikolaas Iridium Kanker Netwerk Introduction Multiple myeloma = Kahler s disease Dr.

More information

Incidence of amyloidosis over 3 years: the AMYPRO study

Incidence of amyloidosis over 3 years: the AMYPRO study Incidence of amyloidosis over 3 years: the AMYPRO study N. Magy-Bertrand 1, J.-L. Dupond 1, F. Mauny 2, A.-S. Dupond 3, F. Duchene 4, H. Gil 1, B. Kantelip 5, and the CRISAP Members 1 Department of Internal

More information

Cardiac Involvement is Underdiagnosed in Patients with Biopsy-Proven Systemic AL Amyloidosis

Cardiac Involvement is Underdiagnosed in Patients with Biopsy-Proven Systemic AL Amyloidosis Original Article 41 Cardiac Involvement is Underdiagnosed in Patients with Biopsy-Proven Systemic AL Amyloidosis Haoyi Zheng 1, Amitabha Mazumder 2, Stuart D. Katz 3 1. Cardiac Imaging, The Heart Center,

More information

Multiple myeloma evolves from a clinically silent premalignant

Multiple myeloma evolves from a clinically silent premalignant S. VINCENT RAJKUMAR Updated Diagnostic Criteria and Staging System for Multiple Myeloma S. Vincent Rajkumar, MD OVERVIEW There has been remarkable progress made in the diagnosis and treatment of multiple

More information

Heart Failure Syndromes related to Unusual Cardiomyopathies

Heart Failure Syndromes related to Unusual Cardiomyopathies Heart Failure Syndromes related to Unusual Cardiomyopathies Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine

More information

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance S. Vincent

More information

Amyloid Arthropathy of the Hip Joint Associated with Multiple Myeloma: A Case Report

Amyloid Arthropathy of the Hip Joint Associated with Multiple Myeloma: A Case Report CSE REPORT Hip Pelvis 28(2): 127-131, 2016 http://dx.doi.org/10.5371/hp.2016.28.2.127 Print ISSN 2287-3260 Online ISSN 2287-3279 myloid rthropathy of the Hip Joint ssociated with Multiple Myeloma: Case

More information

The Utility Of Congo Red Stain And Cytokeratin Immunostain In The Detection Of Primary Cutaneous Amyloidosis

The Utility Of Congo Red Stain And Cytokeratin Immunostain In The Detection Of Primary Cutaneous Amyloidosis ISPUB.COM The Internet Journal of Pathology Volume 17 Number 1 The Utility Of Congo Red Stain And Cytokeratin Immunostain In The Detection Of Primary Cutaneous A,A Citation A, A.. The Internet Journal

More information

Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience

Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience ORIGINAL ARTICLE Korean J Intern Med 2015;30:496-505 Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience A Young Lim 1, Ji Hyeon Lee 1,

More information

Instructions for Plasma Cell Disorders (PCD) Post-HCT Data (Form 2116 Revision 3)

Instructions for Plasma Cell Disorders (PCD) Post-HCT Data (Form 2116 Revision 3) (Form 2116 Revision 3) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Plasma Cell Disorders (PCD) Post-HCT Data Form. E-mail comments regarding the

More information

CASE 3 AN UNUSUAL CASE OF NEPHROTIC SYNDROME

CASE 3 AN UNUSUAL CASE OF NEPHROTIC SYNDROME CASE 3 AN UNUSUAL CASE OF NEPHROTIC SYNDROME Dr Seethalekshmy N.V., Dr.Annie Jojo, Dr Hiran K.R., Amrita institute of Medical Sciences, Kochi, Kerala Case history 34 year old gentleman Nephrotic range

More information

The ABCs of Waldenström s Macroglobulinemia (WM)

The ABCs of Waldenström s Macroglobulinemia (WM) The ABCs of Waldenström s Macroglobulinemia (WM) Jeffrey V. Matous MD Colorado Blood Cancer Institute IWMF Ed Forum May 2017 Objectives Describe the roots underneath WM Review incidence, possible risk

More information

Amyloidosis and Waldenström s Macroglobulinemia

Amyloidosis and Waldenström s Macroglobulinemia Amyloidosis and Waldenström s Macroglobulinemia Morie A. Gertz, Giampaolo Merlini, and Steven P. Treon Primary systemic amyloidosis is an immunoglobulin light chain disorder that is 1/5th as common as

More information

Generalized Primary Amyloid Lymphadenopathy

Generalized Primary Amyloid Lymphadenopathy Korean J Hematol Vol. 44, No. 4, December, 2009 Case Report Generalized Primary Amyloid Lymphadenopathy Jin Hyun Park, M.D. 2, Ji Hyun Kwon, M.D. 2, Ji Won Kim, M.D. 2, Hyeon Jin Cho, M.D. 2, Ki Hwan Kim,

More information

Hevylite assays de - convoluted. Dr Karthik Ramasamy Oxford University Hospitals

Hevylite assays de - convoluted. Dr Karthik Ramasamy Oxford University Hospitals Hevylite assays de - convoluted Dr Karthik Ramasamy Oxford University Hospitals Overview Hevylite assay Introduction Clinical utility of Hevylite 2 Hevylite specifici.es Hevylite specifici.es Hevylite

More information

: A Study Examining the Prevalence of Transthyretin Mutations in Subjects Suspected of Having Cardiac Amyloidosis

: A Study Examining the Prevalence of Transthyretin Mutations in Subjects Suspected of Having Cardiac Amyloidosis : A Study Examining the Prevalence of Transthyretin Mutations in Subjects Suspected of Having Cardiac Amyloidosis 02 November 2015 1 Background and Rationale Cardiac amyloidosis is caused by extracellular

More information

Comparison of amyloid deposition in human kidney biopsies as predictor of poor patient outcome

Comparison of amyloid deposition in human kidney biopsies as predictor of poor patient outcome Castano et al. BMC Nephrology (2015) 16:64 DOI 10.1186/s12882-015-0046-0 RESEARCH ARTICLE Comparison of amyloid deposition in human kidney biopsies as predictor of poor patient outcome Open Access Ekaterina

More information

Malcolm P. McTaggart, PhD, 1 Jindriska Lindsay, FRCPath, 2 and Edward M. Kearney, FRCPath 1 ABSTRACT

Malcolm P. McTaggart, PhD, 1 Jindriska Lindsay, FRCPath, 2 and Edward M. Kearney, FRCPath 1 ABSTRACT Replacing Urine Protein Electrophoresis With Serum Free Light Chain Analysis as a First-Line Test for Detecting Plasma Cell Disorders Offers Increased Diagnostic Accuracy and Potential Health Benefit to

More information

IMAGING IN CARDIAC AMYLOIDOSIS ; TRENDS IN DIAGNOSIS AND GUIDING THERAPY

IMAGING IN CARDIAC AMYLOIDOSIS ; TRENDS IN DIAGNOSIS AND GUIDING THERAPY IMAGING IN CARDIAC AMYLOIDOSIS ; TRENDS IN DIAGNOSIS AND GUIDING THERAPY Mohamed Abo Mandour, MD. Al-Azhar University Cardiac amyloidosis is an under appreciated cause of HF The bottom line pathologic

More information

A Problem with Cardiac Amyloidosis. Defining Amyloidosis. Typical Amyloid Heart. Definition of a double-blind study:

A Problem with Cardiac Amyloidosis. Defining Amyloidosis. Typical Amyloid Heart. Definition of a double-blind study: A disease caused by the deposition of a proteinaceous material, derived from the misfolded breakdown products of a normal or abnormal protein. Typical Amyloid Heart Defining Amyloidosis TYPEOF AMYLOID

More information

Management of Multiple Myeloma

Management of Multiple Myeloma Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.

More information

Hevylite : a New Serum Test for Assessing Patients with Multiple Myeloma

Hevylite : a New Serum Test for Assessing Patients with Multiple Myeloma Hevyite : a New Serum Test for Assessing Patients with Mutipe Myeoma Judith A. Finay, Ph.D. Director of Scientific Affairs The Binding Site, Inc. San Diego, CA 800-633-4484 X335 Some of the subject matter

More information

Criteria for Disease Assessment Joan Bladé

Criteria for Disease Assessment Joan Bladé Criteria for Disease Assessment Joan Bladé Unidad de Amiloidosis y Mieloma Servicio de Hematología Hospital Clínic de Barcelona COMy Meeting, París, May 4th, 2018 Response Evaluation EBMT, 1998 - CR and

More information

Amyloidosis. Philip Hawkins National Amyloidosis Centre UCL & Royal Free Hospital, London

Amyloidosis. Philip Hawkins National Amyloidosis Centre UCL & Royal Free Hospital, London Amyloidosis Philip Hawkins National Amyloidosis Centre UCL & Royal Free Hospital, London Amyloid Abnormal extracellular fibrillar protein deposit in tissues Pathognomonic red-green birefringence after

More information

Research Article Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia

Research Article Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia Advances in Hematology Volume 2013, Article ID 359071, 7 pages http://dx.doi.org/10.1155/2013/359071 Research Article Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia

More information

Amyloidosis for Practicing Hematologists

Amyloidosis for Practicing Hematologists Amyloidosis for Practicing Hematologists Vishal Kukreti, MD Princess Margaret Cancer Centre October 2, 2015 Disclosures Honoraria Celgene, Janssen Ortho, Amgen, Lundbeck Objectives Case Approach subtyping,

More information

Monoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH

Monoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH Monoclonal Gammopathies and the Kidney Tibor Nádasdy, MD The Ohio State University, Columbus, OH Monoclonal gammopathy of renal significance (MGRS) Biopsies at OSU (n=475) between 2007 and 2016 AL or AH

More information

Breast amyloidosis: a case report

Breast amyloidosis: a case report Topic: EuRePS Meeting 2015: best five papers Breast amyloidosis: a case report Giulia Boscaini, Marco Pignatti, Giovanni Tazzioli, Giorgio De Santis Department of Plastic, Reconstructive and Aesthetic

More information

Amyloidosis. James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center. Professor of Medicine Eastern Virginia Medical

Amyloidosis. James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center. Professor of Medicine Eastern Virginia Medical Amyloidosis James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Professor of Medicine Eastern Virginia Medical School www.starkoncology.com 68 y.o. man admitted to MMC in March,

More information

V. Smoldering multiple myeloma

V. Smoldering multiple myeloma Hematological Oncology Hematol Oncol 2015; 33: 33 37 Published online in Wiley Online Library (wileyonlinelibrary.com).2213 Supplement Article V. Smoldering multiple myeloma María-Victoria Mateos 1 * and

More information

TESTS AND INVESTIGATIONS FOR MULTIPLE MYELOMA A guide for patients and caregivers

TESTS AND INVESTIGATIONS FOR MULTIPLE MYELOMA A guide for patients and caregivers TESTS AND INVESTIGATIONS FOR MULTIPLE MYELOMA A guide for patients and caregivers Developed by the Myeloma Special Practice Network (M-SPN) of the Haematology Society of Australia and New Zealand (HSANZ)

More information

30 Diagnostic Cytopathology, Vol 37, No 1 ' 2008 WILEY-LISS, INC.

30 Diagnostic Cytopathology, Vol 37, No 1 ' 2008 WILEY-LISS, INC. Computer-Assisted Image Analysis of Amyloid Deposits in Abdominal Fat Pad Aspiration Biopsies Svetoslav Bardarov, M.D., Claire W. Michael, M.D., Robert T. Pu, M.D., Ph.D., and Yijun Pang, M.D., Ph.D.*

More information

Amyloidosis is a generic term for a group of diseases

Amyloidosis is a generic term for a group of diseases Typing of Amyloidosis in Renal Biopsies Diagnostic Pitfalls Anjali A. Satoskar, MD; Kelly Burdge, MD; Daniel J. Cowden, MD; Gyongyi M. Nadasdy, MD; Lee A. Hebert, MD; Tibor Nadasdy, MD Context. Amyloidosis

More information

Original Article Primary localized amyloidosis of the urinary tract frequently mimics neoplasia: a clinicopathologic analysis of 11 cases

Original Article Primary localized amyloidosis of the urinary tract frequently mimics neoplasia: a clinicopathologic analysis of 11 cases Am J Clin Exp Urol 2014;2(1):71-75 www.ajceu.us /ISSN:2330-1910/AJCEU0000291 Original Article Primary localized amyloidosis of the urinary tract frequently mimics neoplasia: a clinicopathologic analysis

More information

Primary Amyloidosis. Kihyun Kim Div. of Hematology/Oncology, Dept. of Medicine, Sungkyunkwan Univ. School of Medidine Samsung Medical Center

Primary Amyloidosis. Kihyun Kim Div. of Hematology/Oncology, Dept. of Medicine, Sungkyunkwan Univ. School of Medidine Samsung Medical Center Primary Amyloidosis Kihyun Kim Div. of Hematology/Oncology, Dept. of Medicine, Sungkyunkwan Univ. School of Medidine Samsung Medical Center Systemic Amyloidosis A group of complex diseases caused by tissue

More information

Jo Abraham MD Division of Nephrology University of Utah

Jo Abraham MD Division of Nephrology University of Utah Jo Abraham MD Division of Nephrology University of Utah 68 year old male presented 3 weeks ago with a 3 month history of increasing fatigue He reported a 1 week history of increasing dyspnea with a productive

More information

Multiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015

Multiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015 Multiple Myeloma: diagnosis and prognostic factors N Meuleman May 2015 Diagnosis Diagnostic assessment of myeloma: what should we know? Is it really a myeloma? Is there a need for treatment? What is the

More information

Anaemias and other Pesky Haematology Questions

Anaemias and other Pesky Haematology Questions Anaemias and other Pesky Haematology Questions 3 main topics How do I work out an anaemia.. That oh too common paraprotein patient. Those mildly raised lymphocyte count GP discussed patient with me over

More information

Multiple Myeloma Early Detection, Diagnosis, and Staging

Multiple Myeloma Early Detection, Diagnosis, and Staging Multiple Myeloma Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be

More information

Smoldering Myeloma: Leave them alone!

Smoldering Myeloma: Leave them alone! Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002

More information

Amiloidosi AL: clinica, esami diagnostici e prognosi

Amiloidosi AL: clinica, esami diagnostici e prognosi Titolo relazione Amiloidosi AL: clinica, esami diagnostici e prognosi Giovanni Palladini Amyloidosis: protein misfolding disease! Titolo relazione Clinical presentation of the most common forms of Titolo

More information

Case Report AL-Amyloidosis Presenting with Negative Congo Red Staining in the Setting of High Clinical Suspicion: A Case Report

Case Report AL-Amyloidosis Presenting with Negative Congo Red Staining in the Setting of High Clinical Suspicion: A Case Report Case Reports in Nephrology Volume 2012, Article ID 593460, 4 pages doi:10.1155/2012/593460 Case Report AL-Amyloidosis Presenting with Negative Congo Red Staining in the Setting of High Clinical Suspicion:

More information

Update in Nuclear Imaging of Amyloidosis and Sarcoidosis

Update in Nuclear Imaging of Amyloidosis and Sarcoidosis Update in Nuclear Imaging of Amyloidosis and Sarcoidosis Balaji Tamarappoo MD, PhD, Cedars-Sinai Heart Institute and Biomedical Imaging Research Institute Cedars-Sinai Medical Center Los Angeles, CA, USA.

More information

Histopathology: Glomerulonephritis and other renal pathology

Histopathology: Glomerulonephritis and other renal pathology Histopathology: Glomerulonephritis and other renal pathology These presentations are to help you identify basic histopathological features. They do not contain the additional factual information that you

More information

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Present the basic diagnostic features of the commonest conditions causing proteinuria & haematuria Highlight diagnostic pitfalls Nephrotic

More information

Case 3. ACCME/Disclosure. Laboratory results. Clinical history 4/13/2016

Case 3. ACCME/Disclosure. Laboratory results. Clinical history 4/13/2016 Case 3 Lynn D. Cornell, M.D. Mayo Clinic, Rochester, MN Cornell.Lynn@mayo.edu USCAP Renal Case Conference March 13, 2016 ACCME/Disclosure Dr. Cornell has nothing to disclose Clinical history 57-year-old

More information

Bone Marrow Core Biopsy Specimens in AL (Primary) Amyloidosis A Morphologic and Immunohistochemical Study of 100 Cases

Bone Marrow Core Biopsy Specimens in AL (Primary) Amyloidosis A Morphologic and Immunohistochemical Study of 100 Cases Hematopathology / BONE MARROW BIOPSY IN AL AMYLOIDOSIS Bone Marrow Core Biopsy Specimens in AL (Primary) Amyloidosis A Morphologic and Immunohistochemical Study of 100 Cases Niall Swan, MD, 1,2 Martha

More information

Early View Article: Online published version of an accepted article before publication in the final form.

Early View Article: Online published version of an accepted article before publication in the final form. Early View Article: Online published version of an accepted article before publication in the final form. Journal Name: Journal of Case Reports and Images in Oncology Type of Article: Case Report Title:

More information

Amyloidosis is caused by extracellular deposition of

Amyloidosis is caused by extracellular deposition of Mass Spectrometry Based Proteomic Diagnosis of Renal Immunoglobulin Heavy Chain Amyloidosis Sanjeev Sethi,* Jason D. Theis,* Nelson Leung, Angela Dispenzieri,* Samih H. Nasr,* Mary E. Fidler,* Lynn D.

More information

Clinical Study Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease

Clinical Study Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease International Rheumatology Volume 2013, Article ID 426759, 6 pages http://dx.doi.org/10.1155/2013/426759 Clinical Study Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease Aurélie

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: patisiran_onpattro 11/2018 n/a 5/2019 2/2019 Description of Procedure or Service is a double-stranded small

More information

Update on Treatments for Systemic Amyloidosis

Update on Treatments for Systemic Amyloidosis Update on Treatments for Systemic Amyloidosis Laura M. Dember, M.D. Renal, Electrolyte and Hypertension Division University of Pennsylvania ANZSN Update Course Darwin, Australia September 2, 2017 Disclosure

More information

reversing familial amyloid polyneuropathy naturally the raw vegan plant based detoxification regeneration workbook for healing patients volume 2

reversing familial amyloid polyneuropathy naturally the raw vegan plant based detoxification regeneration workbook for healing patients volume 2 DOWNLOAD OR READ : REVERSING FAMILIAL AMYLOID POLYNEUROPATHY NATURALLY THE RAW VEGAN PLANT BASED DETOXIFICATION REGENERATION WORKBOOK FOR HEALING PATIENTS VOLUME 2 PDF EBOOK EPUB MOBI Page 1 Page 2 healing

More information

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Plan of attack: Diagnostic approach to the renal biopsy Differential diagnosis of the clinical syndromes of renal disease Microscopy Step

More information

Case Report A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits That Showed Predominantly Membranous Features

Case Report A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits That Showed Predominantly Membranous Features Hindawi Case Reports in Nephrology Volume 2017, Article ID 1027376, 5 pages https://doi.org/10.1155/2017/1027376 Case Report A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits That

More information

Velcade (bortezomib)

Velcade (bortezomib) Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 03/09/2004 Current Effective Date: 05/01/2017 POLICY A. INDICATIONS The indications below

More information

Multiple intra-renal pathological injury patterns in resistant myeloma

Multiple intra-renal pathological injury patterns in resistant myeloma Multiple intra-renal pathological injury patterns in resistant myeloma Dharshan Rangaswamy 1, Mohit Madken 1, Mahesha Vankalakunti 2, Ravindra Prabhu Attur 1, and Shankar Prasad Nagaraju 1 1. Department

More information

CARDIAC AMYLOIDOSIS IMAGING ERIC MARTIN MD

CARDIAC AMYLOIDOSIS IMAGING ERIC MARTIN MD CARDIAC AMYLOIDOSIS IMAGING ERIC MARTIN MD DISCLOSURES Bayer Dalcor Pharma UK LTD Harvard Clinical Research Institute Heartflow Inc. NIH Vascular Dynamics Employee-Iowa Heart Center/Mercy-Des Moines BACKGROUND

More information

Corporate Presentation

Corporate Presentation Corporate Presentation Disclaimer Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe harbor provisions of the Private

More information

Suspecting Tumors, or Could it be cancer?

Suspecting Tumors, or Could it be cancer? Suspecting Tumors, or Could it be cancer? Donna E. Reece, M.D. Princess Margaret Cancer Centre University Health Network Toronto, ON CANADA 07 February 2018 Background Low back pain is common However,

More information

Forms Revision: Myeloma Changes

Forms Revision: Myeloma Changes Sharing knowledge. Sharing hope. Forms Revision: Myeloma Changes J. Brunner, PA-C and A. Dispenzieri, MD February 2013 Disclosures Janet Brunner, PA-C I have no relevant conflicts of interest to disclose.

More information

THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) THE PHYSICIAN S GUIDE TO AMYLOIDOSIS

THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) THE PHYSICIAN S GUIDE TO AMYLOIDOSIS THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) THE PHYSICIAN S GUIDE TO AMYLOIDOSIS The National Organization for Rare Disorders (NORD) INTRODUCTION This booklet is the eighth in a series of free

More information

Diabetes, Obesity and Heavy Proteinuria

Diabetes, Obesity and Heavy Proteinuria Diabetes, Obesity and Heavy Proteinuria Clinical Case 41 yo Black woman with heavy proteinuria History 2014: noted to have proteinuria on routine lab testing (1.1g/g). 1+ edema. Blood pressure has been

More information

Diagnostic approach to cardiac amyloidosis: A case report

Diagnostic approach to cardiac amyloidosis: A case report Diagnostic approach to cardiac amyloidosis: A case report Georgia Vogiatzi, MD, MSc, PhD 1 st Cardiology Department, Hippokration Hospital, Athens Medical School Disclosures I have no relevant relationships

More information

Plasma cell myeloma (multiple myeloma)

Plasma cell myeloma (multiple myeloma) Plasma cell myeloma (multiple myeloma) Common lymphoid neoplasm, present at old age (70 years average) Remember: plasma cells are terminally differentiated B-lymphocytes that produces antibodies. B-cells

More information

Myeloma Support Group: Now and the Horizon. Brian McClune, DO

Myeloma Support Group: Now and the Horizon. Brian McClune, DO Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?

More information

Protocol. Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis

Protocol. Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis Protocol Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis (80142) Medical Benefit Effective Date: 04/01/13 Next Review Date: 07/15 Preauthorization Yes Review Dates: 04/07, 05/08, 01/10,

More information

Systemic amyloidosis with cardiac involvement

Systemic amyloidosis with cardiac involvement 034 Cardiology Systemic amyloidosis with cardiac involvement Amyloidosis is a term used to describe a group of disorders consisting of abnormalities in and the accumulation of amyloid protein. This protein

More information